Get ready for a thrilling ride into the world of ASX healthcare stocks! The Bell Potter upgrade on Neuren Pharmaceuticals is a game-changer. But here's where it gets controversial...
Neuren Pharmaceuticals, a biopharmaceutical powerhouse, has been making waves with its innovative therapies for neurodevelopmental disorders. And Bell Potter is taking notice!
The Key Takeaway: Bell Potter maintains its 'Buy' rating and has increased its target price for Neuren, indicating a bright future for this ASX healthcare stock.
Let's dive deeper into the reasons behind this exciting development.
The Story Behind the Upgrade: Bell Potter's latest report highlights the expected momentum in Daybue sales, a key treatment developed by Neuren. This growth is attributed to an increase in community-based patient starts in the US, where a significant portion of Rett syndrome patients are treated.
And this is the part most people miss... The broker also anticipates a growing number of patients who have been on Daybue for over a year, leading to more stable demand and sales. With a target price raised to $25, there's an anticipated 16% upside based on current share prices.
But wait, there's more! Despite Neuren's impressive performance in 2025, Bell Potter believes there's still room for growth. The broker expects another strong quarter of Daybue sales growth in the US, driven by expanded sales coverage and community-based patient starts.
The Bottom Line: Bell Potter's forecast remains unchanged, but the target price has increased, indicating confidence in Neuren's future profitability.
So, what do you think? Is Neuren Pharmaceuticals a stock worth investing in? Share your thoughts and opinions in the comments below! We'd love to hear your insights and predictions for this ASX healthcare stock.
